Indonesia.md, the Indonesian healthcare-focused division of Borderless Healthcare Group, is set to develop a solution to support the shortage of specialists in the largest healthcare market in Southeast Asia.

PRESS RELEASE

EMBARGOED UNTIL Thursday, 20th November 2025, at 9:00AM JKT

Indonesia Converges Advanced Medtech, AI, Medical Cloud and Regional Specialists on a Unified Platform – Indonesia.md – to Supercharge Its Heartcare System

Indonesia – 20th November 2025. Indonesia.md, the Indonesia-focused division of Borderless Healthcare Group, announced a major step forward in transforming the country’s heartcare ecosystem by unifying advanced medtech, artificial intelligence, medical cloud infrastructure, and top regional cardiac specialists on a single collaborative platform.
Heart disease remains one of Indonesia’s deadliest health threats. Indonesia.md aims to counter this challenge through a comprehensive suite of innovations, including cross-border medical-cloud collaboration, the world’s smallest and lightest artificial heart assist device, AI-assisted care, and strategic genomic and epigenetic analysis. While addressing the critical sick-care burden, these advancements also pave the way for predictive, preventive, and precision heartcare for Indonesian communities.
To support this mission, Indonesia.md has also launched a national “Heartspan” initiative, a heart longevity-centric omnichannel public education platform where cardiologists, cardiovascular surgeons, scientists, and medtech innovators can develop a heart longevity community with health and wellness influencers and the public.
Rising Need for Advanced Cardiac Solutions Indonesia faces over 10 million heart-failure cases, with mortality exceeding 34% in the absence of a strong artificial heart assist device implant program. Heart transplantation remains rare due to limited organ donation within the predominantly Muslim population.
To address this urgent need, Indonesia.md has secured exclusive rights to introduce a next-generation artificial heart assist device in Indonesia. Developed in Shenzhen, the device is the smallest and lightest of its kind currently available and is designed for long-term assistance for patients with severe heart failure. This device is being used by more than 100 hospitals in China, including the globally renowned largest cardiac centre in the world, Fuwai Hospital in Beijing. More than 1,000 implantations of this device have been performed, which represents over 50% of the market share for Chinese-made artificial heart assist devices in China.
To further enhance Indonesia’s capability to manage heart failure, Indonesia.md, with the support of the Indonesian Association of Thoracic, Cardiac, and Vascular Surgeons (HBTKVI), recently organized a webinar on artificial heart assist devices, which was attended by more than 80% of Indonesia’s cardiothoracic surgeons. Dr Lim Chong Hee, who performed the first U.S.-made artificial heart assist device implantation in Asia, is one of the key contributors to this initiative.
Dr Lim, now a founding stakeholder in Indonesia.md, also recently underwent training with Dr. Yan Efrata Sembiring, a leading cardiothoracic surgeon from Surabaya. Dr. Sembiring, trained in Singapore and Sydney, is also the Vice-Chairman of HBTKVI. The training took place at Fuwai Hospital in Beijing, the world’s largest cardiac centre, and Wuhan Asia Heart Hospital, China’s largest private cardiac hospital.
“We are excited to save lives in Indonesia with the world’s smallest and lightest artificial heart assist device made in China. These innovations are better suited to the Asian thorax, much more affordable at a fraction of the cost of the U.S.-made device and supported by a lighter battery with a longer battery life,” said Dr. Yan Efrata Sembiring.
AI-Driven Post-Implant Care and Global Connectivity The groundbreaking new artificial heart assist device is expected to receive regulatory approval in Indonesia early next year. Apart from training of doctors, Indonesia.md is developing an AI agent to support post-implant care and is linking Indonesian hospitals with top global cardiac centres of excellence through its proprietary Borderless Medical Cloud.
“We are proud to receive glocal support from leading doctors in Indonesia, China, Singapore and across the world. This is becoming a movement where innovators, scientists, clinicians, cardiologists, surgeons, and allied health professionals such as cardiac nurses, physiotherapists and rehab specialists, come together to build an unprecedented pre- artificial heart assist device implantation patient selection program and post-implantation patient care ecosystem to support this impactful initiative,” said Dr. Wei Siang Yu, Founder and Chairman of Borderless Healthcare Group.
About Indonesia.md Indonesia.md is a Singapore-incorporated division of Borderless Healthcare Group, dedicated to transforming Indonesia’s healthcare ecosystem through medical-cloud infrastructure, advanced medtech integration, AI-enabled care, and cross-border collaboration. The platform supports clinical training, technology transfer, and next-generation patient care—bridging global innovation hubs with local healthcare systems.
About Borderless Healthcare Group Borderless Healthcare Group (BHG) is a global ecosystem builder operating at the intersection of healthcare, medtech, telecommunications, and wellness. By integrating frontier technologies with leading clinical expertise, BHG accelerates the adoption of breakthrough health solutions across emerging markets, connecting innovators, clinicians, investors, and patients worldwide.
Media Contact Lani Santiago VP, Office of the Chairman at Borderless Healthcare Group lani@borderlesshealthcare.com
Indonesia.md is an initiative of Borderless Healthcare Group. All rights reserved. © 2026.